Skip to content

Music Therapy for Pain Modification in Pediatric Palliative Care

Music Therapy as a Pain Modifying Intervention in Children With Life-limiting Neurological Impairments and Metabolic Conditions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01456884
Enrollment
13
Registered
2011-10-21
Start date
2012-01-31
Completion date
2014-08-31
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological Impairment

Keywords

Music therapy, Infants, Children, Adolescents, pediatric, palliative care, neurological impairment, metabolic condition, pain management

Brief summary

The purpose of this within-subjects randomized controlled trial is to determine whether two music therapy interventions are efficacious in reducing pain symptoms, in order to improve the quality of care for children in pediatric hospice. The investigators hypothesize that both music therapy interventions, live guitar and vocal intervention and vibroacoustic intervention, will reduce behavioural pain scores and that behavioural pain scores will correlate with physiological outcome measures.

Detailed description

Effective pain management in pediatric palliative care is a quality of life issue for patients, families and professionals. Current research supports the use of music therapy to assist with pain management in pediatric medical settings. However, little research has been done to explore the use of music therapy for reducing pain in children with life-limiting neurological impairments or metabolic conditions. As the first known project to examine the effects of music therapy on pain symptoms with children who have life-limiting neurological impairments or metabolic disorders, this study will expand the evidence-base for practice with this population. It is imperative that an evidence base for music therapy in this area be established, so that the most effective interventions can be provided to these vulnerable children.

Interventions

BEHAVIORALVibroacoustic Music Therapy

30 minutes using vibroacoustic mat.

BEHAVIORALLive guitar and vocal music therapy

Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.

Sponsors

American Music Therapy Association
CollaboratorOTHER
Canuck Place Children's Hospice
CollaboratorUNKNOWN
Child and Family Research Institute
CollaboratorOTHER
BC Women's Hospital and Health Centre
CollaboratorUNKNOWN
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Months to 19 Years
Healthy volunteers
No

Inclusion criteria

* Children, ages 1-19, who have been diagnosed with life-limiting neurological impairments and metabolic conditions * Cognitive functioning level of one year or less will be enrolled in the study * Receiving respite or symptom management care at the time of admission to the Canuck Place Children's Hospice * Guardians must be able to provide written consent in English; interpreters will be available if a guardian needs clarification on specific points.

Exclusion criteria

* Children who are actively dying (i.e. admitted for end-of-life care or determined by physicians to require immediate end-of-life care) * Any history of adverse responses to live or recorded music or to vibroacoustic stimulation * Severe to profound hearing impairment will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Behavioural Pain ScoresParticipants will be observed for a total of 3 hours during one hospice admission, an expected average of one weekNon-communicating children's pain checklist scores.

Secondary

MeasureTime frameDescription
Physiological measuresParticipants will be observed for a total of 3 hours during one hospice admission, an expected average of one weekHeart rate, oxygen saturation, skin conductance

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026